S Corm
Overview
Explore the profile of S Corm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hochart C, Berthon C, Corm S, Gay J, Cliquennois M, Tricot S, et al.
Med Mal Infect
. 2011 Nov;
41(12):652-6.
PMID: 22056376
Background: Adult leukemia patients with febrile neutropenia have a higher volume of distribution requiring increased drug doses. We performed a survey of vancomycin use in that population to assess the...
2.
des Champs-Bro B, Leroy-Cotteau A, Mazingue F, Pasquier F, Francois N, Corm S, et al.
J Clin Pharm Ther
. 2011 Mar;
36(2):152-60.
PMID: 21366643
What Is Known And Objective: Invasive fungal infections (IFI) are associated with high rates of morbidity and mortality, particularly in onco-haematology patients. We aimed to study the epidemiology of IFI...
3.
Rea D, Etienne G, Corm S, Cony-Makhoul P, Gardembas M, Legros L, et al.
Leukemia
. 2009 Feb;
23(6):1193-6.
PMID: 19242496
No abstract available.
4.
Douet-Guilbert N, Lai J, Basinko A, Gueganic N, Andrieux J, Pollet B, et al.
Br J Haematol
. 2008 Nov;
143(5):716-20.
PMID: 19036015
Isochromosome of the long arm of chromosome 20 with loss of interstitial material [ider(20q)] is a variant of deletion of chromosome 20q and a rare abnormality in myelodysplastic syndrome (MDS)....
5.
Cortes J, Kim D, Raffoux E, Martinelli G, Ritchie E, Roy L, et al.
Leukemia
. 2008 Aug;
22(12):2176-83.
PMID: 18754032
Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally (70...
6.
Hochhaus A, Baccarani M, Deininger M, Apperley J, Lipton J, Goldberg S, et al.
Leukemia
. 2008 Apr;
22(6):1200-6.
PMID: 18401416
Dasatinib, a potent inhibitor of BCR-ABL in vitro, is effective for patients with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. To provide a more definitive assessment of dasatinib...
7.
Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N, et al.
Leukemia
. 2008 Jan;
22(4):791-9.
PMID: 18216868
Patients with chronic myeloid leukemia who become resistant to the Abl kinase inhibitor imatinib can be treated with dasatinib. This sequential treatment can lead to BCR-ABL mutations conferring broad resistance...
8.
Corm S, Renneville A, Rad-Quesnel E, Grardel N, Preudhomme C, Quesnel B
Leukemia
. 2007 Jun;
21(11):2376-7.
PMID: 17554376
No abstract available.
9.
Nicolini F, Corm S, Le Q, Roche-Lestienne C, Preudhomme C
Leukemia
. 2007 Jan;
21(2):193-4.
PMID: 17251899
No abstract available.
10.
Nicolini F, Corm S, Le Q, Sorel N, Hayette S, Bories D, et al.
Leukemia
. 2006 Apr;
20(6):1061-6.
PMID: 16642048
The emergence of ABL point mutations is the most frequent cause for imatinib resistance in chronic myelogenous leukemia (CML) patients and can occur during any phase of the disease; however,...